TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05655182: A Study of BLB-201 RSV Vaccine in Infants and Children

Sponsor: Blue Lake Biotechnology Inc. · Phase: PHASE1/PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 137 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$1,649,340

Rescue Site Savings

+$1,099,560

Unlock Full NCT05655182 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05655182 Rescue Dossier →